The effect of the pneumococcal conjugate vaccine immunization programme on pneumococcal-associated or potentially pneumococcal-associated hospital admissions in the Italian region of Liguria was assessed. Hospital admission rates were compared in subjects belonging to birth cohorts before and after the introduction of widespread immunization for 0 -2-year old children with a seven-valent conjugate vaccine (PCV7). Significant reductions in hospitalization rates for all-cause and pneumococcal pneumonia and for acute otitis media were observed in subjects born after widespread uptake of the vaccine. The preventive fraction (a measure of vaccine effectiveness) ranged from 15.2% for allcause pneumonia to 70.5% for pneumococcal pneumonia. This study contributes to the growing body of information that supports the beneficial effect of PCV7 vaccination.
Introduction
Streptococcus pneumoniae (pneumococcus) is a leading cause of invasive pneumococcal diseases including septicaemia and meningitis, as well as non-invasive infections such as community-acquired pneumonia and acute otitis media. Specific epidemiological patterns and burdens (including incidence, serotype distribution, prevalence of high-risk subjects, hospitalizations and deaths) are substantially different in different areas of the world. 1, 2 In February 2000, a sevenvalent conjugate vaccine (PCV7; Prevenar ® , Wyeth Pharmaceuticals, Collegeville, PA, USA) was approved in the USA for use in children < 2 years of age. Within 1 year of its routine use, the incidence of vaccineserotype invasive pneumococcal disease had fallen dramatically, with indirect effects also noted among other age groups. 3 This vaccine has now been approved in over 70 countries and over 100 million doses have been distributed to date. PCV7 was approved by the European Medicines Agency (EMEA) in February 2001 and has been available in some European countries, such as Spain, F Ansaldi, L Sticchi, P Durando et al. 4 The present study looked at the effect of the PCV7 immunization programme on pneumococcal-associated or potentially pneumococcal-associated hospital admissions in the administrative region of Liguria, Italy.
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Subjects and methods
STUDY POPULATION AND DATA SOURCE
The administrative region of Liguria, Italy, has a population of 1 572 000 inhabitants and every 1-year birth cohort includes about 12 000 newborns. Five Local Health Units (LHUs) are located in this region. In May 2003, a large-scale vaccination programme against pneumococcus with PCV7 was started: all newborns were invited to receive the pneumococcal vaccine according to a 3-5-11-month schedule. To assess the effect of the immunization programme on pneumococcalassociated or potentially pneumococcalassociated admissions, data were analysed from the Liguria regional database covering all-cause and pneumococcal pneumonia, acute otitis media, meningitis and septicaemia admission rates. For every in-patient, discharge information on hospitalization, diagnosis and procedures performed during the hospitalization were included in a central database, in accordance with the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). 5 This database was used as a data source for discharge diagnosis. Admission rates observed in subjects belonging to birth cohorts before (2000 -2002) and after (2003 -2005) introduction of the immunization programme in the first 2 years of life were compared. The PCV7 vaccine coverage data were obtained from the LHU databases.
CLINICAL OUTCOME MEASURES
The primary outcome was the comparison of pneumococcal-associated or potentially pneumococcal-associated hospitalizations in subjects born before and after introduction of the immunization programme. All-cause and pneumococcal pneumonia, acute otitis media, meningitis and septicaemia admissions were identified by their principal or secondary diagnosis ICD-9-CM codes. To improve the sensitivity and accuracy of coding data for the identification of pneumococcal pneumonia, the specific ICD-9-CM code was searched in all five positions of the discharge record. 6 ICD-9-CM codes used for the analysis were: all-cause pneumonia, 480 -487.0; pneumococcal pneumonia, 481; acute otitis media, 382, 382.0, 382.9; meningitis, 320, 322 -322.9; septicaemia, 038.
Urinary tract infections (UTIs) which included the 599.0 ICD-9-CM code were considered to be non-specific outcome unrelated to pneumococcal disease, and were used to evaluate the specificity of the outcome evaluation.
STATISTICAL ANALYSIS
Crude event-and age-specific rates were calculated by dividing the number of hospitalizations by the person-time for each outcome and each age band. Results are presented as incidence before and after introduction of the vaccination programme, and preventive fraction (95% confidence interval). The population figure obtained by census was used in all calculations.
Results
The numbers of residents born before and F Ansaldi, L Sticchi, P Durando et al. Among the subjects belonging to birth cohorts before and after introduction of the immunization programme, 830 and 700 cases of pneumococcal-associated or potentially pneumococcal-associated hospital admissions, respectively, were registered. There were significantly higher hospitalization rates in the birth cohorts before introduction of the programme for the 7 -12-month (126.1/ 10 000 versus 102.1/10 000 person-years, P = 0.03) and 13 -24-month (115.4/10 000 versus 78.9/10 000 person-years, P < 0.001) age groups.
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Hospitalization rates according to discharge coding showed significant reductions for all-cause and for pneumococcal pneumonia (P < 0.05) and for acute otitis media (P < 0.01) in subjects born after introduction of the vaccination programme (Table 1 ). This shows a preventive fraction due to vaccination ranging from 15.2% for all-cause pneumonia to 70.5% for pneumococcal pneumonia. Figure 1 shows that the decline in hospitalization rates in subjects born before versus after introduction of the vaccination programme varied considerably in these groups according to age class. All-cause pneumonia, pneumococcal pneumonia and acute otitis media hospitalization rates declined in the 0 -6, 7 -12 and 13 -24-month age groups, but statistically significant declines for acute otitis media occurred in the 7 -12-month (P < 0.001) and 13 -24-month age groups (P < 0.001), and for all-cause pneumonia in the 13 -24-month age group (P = 0.006).
No significant changes in hospitalization rates for meningitis, sepsis and the nonspecific outcome variable UTIs were noted when comparing pre-and post-immunization periods in children < 2 years of age. When admission data were stratified for age class, the meningitis hospitalization rate in children born before 2003 was higher in the 13 -24 month age class (1.79/10 000 person-years, 95% CI 0.65 -3.9 versus 0.28/10 000 personyears, 95% CI 0.037 -1.57, P = 0.05). All-cause pneumonia, 0-6 months All-cause pneumonia, 7-12 months All-cause pneumonia, 13-24 months AOM, 0-6 months AOM, 7-12 months AOM, 13-24 months Pn pneumonia, 0-6 months Pn pneumonia, 7-12 months Pn pneumonia, 13-24 months
Incidence
Discussion
Although the results of randomized clinical trials have suggested that PCV7 reduces the incidence of invasive pneumococcal diseases, pneumonia and otitis media, the effect of the PCV7 vaccination campaign on the general population has been poorly reported in Europe, being mainly limited to reports of changes in the incidence of invasive pneumococcal diseases in France and Spain. 4 Evaluation of the effectiveness of PCV7 in different countries is of fundamental importance, because it is largely affected by the incidence of pneumococcal-associated diseases and by the proportion of circulating serotypes that are covered by the composition of the vaccine. The incidence of pneumococcal-associated diseases varies considerably in different areas of the world: prior to the introduction of PCV7 in the USA, reported incidence rates of invasive pneumococcal diseases in children < 2 years old were approximately 188/100 000, whereas data from other regions (such as Europe) ranged between 1.7/100 000 in Sweden and 174/100 000 in Spain in the same age group. 7 This wide range in incidence is due to several factors, including standard medical practices (such as the frequency of bacterial culture confirmation of F Ansaldi, L Sticchi, P Durando et al.
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the disease or the frequency of antibiotic pretreatment) and the available infrastructure (the ability to make an aetiological diagnosis, and the presence of surveillance and/or reporting networks). 1 Serotype distribution studies have also shown substantial variations in the proportion of disease caused by serotypes covered by PCV7 in different populations: in young children, the highest serogroup coverage for PCV7 was reported for the USA, Canada and Australia (80 -90%), followed by Europe and Africa (70 -75%), Latin America (about 65%) and Asia (approximately 50%). 2 The impact of introducing the PCV7 vaccination programme in Liguria, Italy, has been swift and substantial, resulting in a significant decrease in hospitalization rates for all-cause and pneumococcal pneumonia and acute otitis media among children < 2 years old. At the end of 2006, admission rates reported in the present study indicate that about 200 hospitalizations were prevented in the 0 -2-year age group for the abovementioned causes in the three birth cohorts studied for the Liguria region of Italy. The global effect of the vaccination programme is underestimated, since herd effects that have been demonstrated for pneumococcal diseases in unvaccinated subjects > 2 years of age were not evaluated in the present analysis. 8 Although the incidence of all-cause and pneumococcal pneumonia and acute otitis media observed in Liguria, Italy, cannot be compared (for the reasons already mentioned) with available data from other countries, the decline in hospitalization rates observed for pneumococcal pneumonia (70.5%) is close to that estimated by Grijalva et al. 8 (65%) and Zhou et al. 9 (58%). The preventive fraction for acute otitis media (36.4%) reported in the present study is within the range of vaccine efficacy against recurrent otitis media that was reported in a recent review. 10 Some caution should be considered in the interpretation of these results. First, the identification of invasive pneumococcal diseases, pneumonia and acute otitis media admissions based on ICD-9-CM codes could be subject to misclassification, despite these codes being validated for consistency. Secondly, the causative agent of disease is not routinely indicated, which explains the low observed incidence of pneumococcal pneumonia with respect to studies that include laboratory confirmation. It is noteworthy that, although only 2.9% of all-cause pneumonia admissions were coded as pneumococcal pneumonia, there was a substantial decline in the rate of all-cause pneumonia hospitalization (15.2%). This suggests an important aetiological role for pneumococcus and shows the difficulties of accurately diagnosing pneumococcal childhood pneumonia. Several other factors might affect the observed decline in hospitalizations, for example changes in the sampling framework, although admissions due to non-specific outcome of UTIs remained unchanged after implementation of the PCV7 vaccination. Other unpredictable factors (such as a severe influenza epidemic, implementation of influenza vaccination or potential secular trends) might also have influenced the outcomes. Surprisingly, hospitalizations for meningitis and sepsis remained stable after introduction of the immunization programme. Two reasons might explain the lack of decline in these invasive diseases, although the small number of reported cases of meningitis and sepsis limits the significance of this finding. First, diseasespecific infectious morbidity tends to be under-reported 11 and microbiologically identifiable disease may be hidden in the ICD-9-CM code as 'unspecified' disease, 6 underestimating the aetiological role of pneumococcus.
Secondly, a higher of agents other than pneumococcus (Neisseria meningitis and Haemophilus influenza) after the introduction of PCV7 could be responsible for a rise in hospitalizations for meningitis and sepsis. Specific data for meningitis from the Italian surveillance system support this hypothesis: in Liguria, the proportion of laboratoryconfirmed pneumococcal meningitis cases in the first 2 years of life dropped from 50% to 25% in children born before and after the widespread uptake of vaccine, respectively. 12 In conclusion, this quasi-experimental on-field analysis showed a decline in admission rates for pneumonia and acute otitis media in children < 2 years of age after the introduction of PCV7 immunization. This evidence contributes to the growing body of information that supports the beneficial effect of the PCV7 vaccination.
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